Targeting Pathophysiologic Pathways in Cervical Cancer: Why Immunotherapy?

Activity Overview

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate immunotherapy rationale, mechanism of action, and safety considerations in cervical cancer.

0.25 CE Credit(s)

Expires: February 9, 2023

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

Align the mechanism of action of immune checkpoint inhibitors with underlying cervical cancer processes

Activity Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM

Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA

Featured RMEI CE Activities

Identifying Patients at Risk for Advanced NMSC: A Visual Guide

Getting it Right in Crohn’s Disease: A Clinical Guideline and Decision Tool-Based Approach (part 2 of 2)

Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach (part 1 of 2)

Assessing the Potential Implications of New Data in Chronic Spontaneous Urticaria

Privacy | Terms of Use

Targeting Pathophysiologic Pathways in Cervical Cancer: Why Immunotherapy?

Activity Overview

Target Audience

Learning Objectives

Activity Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM

Identifying Patients at Risk for Advanced NMSC: A Visual Guide

Getting it Right in Crohn’s Disease: A Clinical Guideline and Decision Tool-Based Approach (part 2 of 2)

Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach (part 1 of 2)

Assessing the Potential Implications of New Data in Chronic Spontaneous Urticaria

Join Our Network

Company

CE Accreditation

HIPAA Verified & Compliant

Subscribe